Unusual HPRT Expression in Prostate Cancer Cells and its Impact on Potential Treatment
Michelle H. Townsend1, Abi M. Felsted1, Michael D. Anderson1, Richard A. Robison1, Kim L. O’Neill1
1

Department of Microbiology and Molecular Biology, Brigham Young University, Provo UT 84602

Introduction: The purpose of this study is to evaluate the expression and possible upregulation of the salvage
pathway enzyme hypoxanthine guanine phosphoribosyltransferase (HPRT) in prostate cancer cells to determine if
it could serve as a biomarker for prostate cancer diagnosis and potential treatment. In men, prostate cancer is the
second most lethal cancer, and 27,540 men died from the disease in 2015. We chose to evaluate the salvage
pathway enzymes due to a historically known relationship between Thymidine Kinase 1 (TK1), a salvage
pathway enzyme, and prostate cancer. TK1 is a reliable biomarker for prostate cancer detection and development,
which led us to the investigation the other pathway enzymes to determine whether similar relationships were
present in lung cancer.
Materials and Methods: Two prostate cancer cell lines were utilized for this analysis (PC3 and DU145) along
with cancer tissue and healthy tissue from 35 different prostate carcinoma patients. The surface localization of
HPRT was determined utilizing flow cytometry, confocal microscopy, and scanning electron microscopy, while
upregulation within tissue was assessed using immunohistochemistry.
Results: Throughout our investigation, we found a significant association between HPRT and the plasma
membrane of DU145 cells but no presence was observed on PC3 cells. Using fluorescently conjugated antibodies,
flow cytometry analysis showed minimal to zero
changes in cell fluorescence when PC3 cells were
exposed to HPRT antibody. There was a significant
increase in fluorescence when DU145 cells were treated
with HPRT antibody as the average population
fluorescence enlarged by over 30%. This expression is
statistically significant from the fluorescence increase
observed in isotypic IgG controls (p value = 0.0004).
Meanwhile, HPRT binding in PC3 cells was
insignificant (p value = 0.1419). To determine the
distribution of HPRT across the membrane and ensure
the observed expression was not due to cytoplasmic
HPRT, gold conjugated antibodies were used for cell
staining. The distribution of the gold on the cell surface
showed random HPRT binding across the membrane
with no clear pattern of expression. This analysis aided
Figure 1: Flow cytometry analysis of HPRT on PC3 and DU145
in confirming HPRT presence as the gold weight % of
cells. A, Cells exposed to HPRT antibody (pink) showed no
the sample increased significantly when DU145 cells
significant increase in surface expression in PC3 cells. B, statistical
were exposed to HPRT antibody (p-value < 0.0001). In
analysis shows an insignificant increase in fluorescence. C, DU145
cells exposed to HPRT antibody had a significant shift in the
addition to being presented on the surface of non-small
population towards a higher fluorescence indicating antibody
cell lung cancer cells, the general upregulation of the
binding on the surface of the cell. D, statistically analysis reveals a
protein was evaluated in human cancer tissue to
p value less than 0.0001.
determine whether the enzyme had differential
expression in clinically relevant samples. Using IHC, an upregulation of HPRT within cancer tissue was seen
when compared to healthy tissue. Because of the differential expression between these cell lines, this expression
may be limited to only a few types of prostate cancer.
Conclusions: These results strongly indicate a unique relationship between prostate cancer cells and HPRT and
suggest HPRT as a possible biomarker for the detection and potential treatment of some prostate cancers.

